Vertex Pharmaceuticals reported strong growth for 2025, with total revenue of $12.0 billion, up 9% from 2024, and fourth quarter revenue of $3.19 billion, up 10%. Growth was driven by cystic fibrosis (CF) therapies and new products ALYFTREK, CASGEVY and JOURNAVX.
GAAP net income for 2025 was $3.95 billion, compared to a GAAP net loss of $(535.6) million in 2024, which was impacted by acquisition-related R&D. Non-GAAP net income rose to $4.75 billion from $110.6 million. Cash, cash equivalents and marketable securities reached $12.3 billion at year-end.
For 2026, the company guides to total revenue of $12.95–$13.1 billion, including $0.5 billion or more from non-CF products, and plans continued heavy investment in R&D and SG&A while advancing a broad mid- and late-stage pipeline across CF, gene editing, kidney disease, pain, autoimmune and diabetes programs.
Capital Research Global Investors filed a Schedule 13G/A reporting beneficial ownership of 17,319,044 shares of Vertex Pharmaceuticals Inc. common stock, representing 6.8% of the 253,718,831 shares believed to be outstanding as of the event date.
The filer reports sole voting power over 17,303,696 shares and sole dispositive power over 17,319,044 shares, with no shared voting or dispositive power. The securities are certified as acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Vertex.
A shareholder has filed a notice of proposed sales of common stock, indicating an intent to sell 1,925 shares through Fidelity Brokerage Services LLC on or around 02/11/2026 on the NASDAQ. The filing lists an aggregate market value of $886,327.75 for these shares and shows 253,718,831 shares of this class outstanding.
The 1,925 shares were acquired on 02/10/2026 through restricted stock vesting from the issuer as compensation. The document also reports that Jonathan Biller sold 347 common shares for $155,803.00 on 12/03/2025 during the past three months.
Edward Atkinson, a holder of Vertex Pharmaceuticals (VRTX) common stock, has filed a notice of proposed sale of 1,751 common shares through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $806,212.93.
The 1,751 common shares were acquired on 02/10/2026 via restricted stock vesting from the issuer as compensation. The notice also reports that Atkinson sold 2,500 common shares on 11/17/2025 for gross proceeds of $1,086,450.00. Vertex had 253,718,831 common shares outstanding at the time referenced.
A holder of Vertex Pharmaceuticals (VRTX) filed a Rule 144 notice to sell 2,021 common shares through Fidelity Brokerage Services on NASDAQ, with an approximate sale date of 02/11/2026. The filing lists an aggregate market value of $930,529.03 and 253,718,831 shares outstanding.
The 2,021 shares derive from restricted stock vesting on 02/10/2026, received as compensation from the issuer. The filing also notes a prior sale by Mark E. Bunnage of 23 common shares on 12/29/2025 for gross proceeds of $10,649.00.
Ourania Tatsis has filed a Form 144 to sell 466 shares of common stock. The shares were acquired through restricted stock vesting on 02/10/2026 as compensation and are planned to be sold around 02/11/2026 through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $214,560.38.
In the prior three months, Tatsis sold 4,500 common shares on 12/03/2025 for gross proceeds of $2,024,955.40 and another 4,500 shares on 01/07/2026 for $2,137,455.00.
Vertex Pharmaceuticals executive Mark E. Bunnage has filed an initial insider ownership report. As of February 1, 2026, he beneficially owns 16,062 shares of Vertex common stock, held directly. He serves as EVP, Chief Scientific Officer and reports no derivative securities in this filing.
Vertex Pharmaceuticals executive Charles F. Wagner Jr., EVP, CO & FO, reported the acquisition of 13,600 shares of Vertex common stock through earned performance awards. On 01/22/2026, he received 9,440 shares tied to a performance stock unit award granted on 02/01/2023 and 4,160 shares from a performance stock unit award granted on 02/12/2025, both at a price of $0 per share.
The company’s management development and compensation committee certified the performance-goal attainment on 01/22/2026. The 2023 award shares will vest on 02/13/2026, while the 2025 award shares will vest in installments beginning on 02/24/2026. Following these transactions, Wagner directly holds 51,325 shares of Vertex common stock.
Vertex Pharmaceuticals executive Ourania Tatsis reported awards of company stock tied to performance goals. On January 22, 2026, she acquired 7,866 shares of Vertex common stock at $0 per share as earned performance shares from a performance stock unit award originally granted on February 1, 2023. On the same date, she also acquired 3,883 shares at $0 per share as earned performance shares from a separate performance stock unit award granted on February 12, 2025. These awards were triggered after the company’s management development and compensation committee certified that the required performance goals had been met, with the 2023 grant scheduled to vest on February 13, 2026 and the 2025 grant scheduled to vest in installments beginning on February 24, 2026. Following these transactions, Tatsis directly beneficially owned 54,042 shares of Vertex common stock.
Vertex Pharmaceuticals executive Amit Sachdev reported new stock awards tied to performance goals. On 01/22/2026, he acquired 7,866 shares of Vertex common stock and another 3,883 shares at a price of $0 per share, reflecting earned performance stock unit awards granted on 02/01/2023 and 02/12/2025 after the compensation committee certified goal attainment on 01/22/2026. Following these awards, he directly holds 70,998 common shares, with additional indirect holdings of 882 shares in a 401(k) plan and 9,301 shares held in trust. The earned performance shares are scheduled to vest on 02/13/2026 and in installments beginning on 02/24/2026.